FATE
Price
$2.49
Change
-$0.13 (-4.96%)
Updated
Nov 30, 6:59 PM EST
89 days until earnings call
MRKR
Price
$2.76
Change
-$0.14 (-4.83%)
Updated
Nov 30, 6:59 PM EST
Ad is loading...

Compare trend and price FATE vs MRKR

Header iconFATE vs MRKR Comparison
Open Charts FATE vs MRKRBanner chart's image
Fate Therapeutics
Price$2.49
Change-$0.13 (-4.96%)
Volume$1.92M
CapitalizationN/A
Marker Therapeutics
Price$2.76
Change-$0.14 (-4.83%)
Volume$13.51K
CapitalizationN/A
View a ticker or compare two or three
FATE vs MRKR Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
FATE vs. MRKR commentary
Dec 01, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and MRKR is a StrongBuy.

COMPARISON
Comparison
Dec 01, 2023
Stock price -- (FATE: $2.49 vs. MRKR: $2.76)
Brand notoriety: FATE and MRKR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 115% vs. MRKR: 55%
Market capitalization -- FATE: $224.81M vs. MRKR: $24M
FATE [@Biotechnology] is valued at $224.81M. MRKR’s [@Biotechnology] market capitalization is $24M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileMRKR’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • MRKR’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than MRKR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while MRKR’s TA Score has 5 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 5 bearish.
  • MRKR’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, MRKR is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а +4.18% price change this week, while MRKR (@Biotechnology) price change was +2.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.35%. For the same industry, the average monthly price growth was +26.89%, and the average quarterly price growth was +20.28%.

Reported Earning Dates

FATE is expected to report earnings on Feb 27, 2024.

MRKR is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (+2.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for FATE with price predictions.
OPEN
A.I.dvisor published
a Summary for MRKR with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
FATE($225M) has a higher market cap than MRKR($24M). MRKR YTD gains are higher at: 3.799 vs. FATE (-75.322). MRKR has higher annual earnings (EBITDA): -24.84M vs. FATE (-188.62M). FATE has more cash in the bank: 350M vs. MRKR (17.5M). MRKR has less debt than FATE: MRKR (0) vs FATE (105M). FATE has higher revenues than MRKR: FATE (106M) vs MRKR (9.01M).
FATEMRKRFATE / MRKR
Capitalization225M24M938%
EBITDA-188.62M-24.84M759%
Gain YTD-75.3223.799-1,983%
P/E RatioN/AN/A-
Revenue106M9.01M1,176%
Total Cash350M17.5M2,000%
Total Debt105M0-
FUNDAMENTALS RATINGS
FATE vs MRKR: Fundamental Ratings
FATE
MRKR
OUTLOOK RATING
1..100
2618
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
4953
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (16) in the Biotechnology industry is in the same range as MRKR (30) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRKR (100) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's SMR Rating (96) in the Biotechnology industry is in the same range as MRKR (97) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's Price Growth Rating (49) in the Biotechnology industry is in the same range as MRKR (53) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MRKR (100) in the Other Consumer Services industry. This means that FATE’s stock grew similarly to MRKR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEMRKR
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OTIS85.811.48
+1.75%
Otis Worldwide Corp
HBB15.420.20
+1.31%
Hamilton Beach Brands Holding Company
ASO50.870.33
+0.65%
Academy Sports and Outdoors
UNFI14.53-0.18
-1.22%
United Natural Foods
CANO7.38-0.41
-5.26%
Cano Health

MRKR and

Correlation & Price change

A.I.dvisor tells us that MRKR and SRNEQ have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRKR and SRNEQ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRKR
1D Price
Change %
MRKR100%
-4.83%
SRNEQ - MRKR
27%
Poorly correlated
N/A
FATE - MRKR
27%
Poorly correlated
-4.96%
SNPX - MRKR
27%
Poorly correlated
+0.04%
SRRK - MRKR
26%
Poorly correlated
+4.14%
MDGL - MRKR
25%
Poorly correlated
+3.01%
More